Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
3 High-Yielding Dividend Payers That Spent Billions on Share Buybacks Last Quarter
03:00pm, Thursday, 14'th Jul 2022 The Motley Fool
These companies are generating tons of free cash flow.
2 Top Biotech Stocks Defying the Bear Market
02:53pm, Thursday, 14'th Jul 2022 The Motley Fool
AbbVie and Bristol-Myers Squibb are drastically outperforming the S&P 500 index so far this year.
Bear Market Winners: 3 Healthcare Stocks That Have Soared More Than 30% This Year
02:45pm, Thursday, 14'th Jul 2022 The Motley Fool
Have these scorching-hot stocks peaked, or could there still be more gains ahead for investors who buy today?
The Zacks Analyst Blog Highlights The Howard Hughes, Wyndham Hotels & Resorts, Greif, CVR Energy and Avis Budget Group
12:10pm, Thursday, 14'th Jul 2022 Zacks Investment Research
The Howard Hughes, Wyndham Hotels & Resorts, Greif, CVR Energy and Avis Budget Group are part of Zacks top Analyst Blog.
Top Analyst Reports for Pfizer, Raytheon Technologies & Diageo
08:18pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), Raytheon Technologies Corporation (RTX), and Diageo plc (DEO).
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
01:40pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
01:00pm, Wednesday, 13'th Jul 2022 Zacks Investment Research
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Why Novavax Stock Shot Higher Today
09:20pm, Tuesday, 12'th Jul 2022 The Motley Fool
A media report says that the company's coronavirus vaccine is about to be authorized for use in the U.S.
Novavax (NVAX) Inks COVID Jab Supply Deal With US Government
07:31pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Novavax (NVAX) inks a deal with the US government to supply 3.2 million doses of COVID shot. But the deal will be effective only if the vaccine gets EUA from the FDA. It also needs CDC recommendation.
Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5
07:16pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.
Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal
03:57pm, Tuesday, 12'th Jul 2022 Zacks Investment Research
Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.
When the Market Recovers, You'll Want to Own These 2 Healthcare ETFs
02:53pm, Tuesday, 12'th Jul 2022 The Motley Fool
Diseases evolve, accidents happen, the overall population is aging -- and the demand for treatment, services, and insurance is growing.
Novavax Stock: Bear vs. Bull
10:00am, Tuesday, 12'th Jul 2022 The Motley Fool
Can this vaccine latecomer win market share?
Pfizer (PFE) Stock Moves -0.53%: What You Should Know
09:45pm, Monday, 11'th Jul 2022 Zacks Investment Research
Pfizer (PFE) closed the most recent trading day at $52.89, moving -0.53% from the previous trading session.
PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents
07:17pm, Monday, 11'th Jul 2022 Zacks Investment Research
Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.
